NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ:

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
203
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2023 Results, Presents Updated Findings from Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its financial results for the quarter ended June 30, 2023, provided a corporate update and reiterated upcoming milestones. “We are approaching the most important milestone to date since we launched CNS Pharma. We are just a few months away from reporting topline results from our Berubicin potentially pivotal study interim analysis and, although we do not know what the data looks like at this time, we remain hopeful as we also approach full enrollment of the trial,” said John Climaco, CEO of CNS Pharmaceuticals. “Looking ahead, we remain focused on executing on all of our operational efforts and, importantly, taking our Berubicin trial for GBM across the finish line. We are poised for an exciting remainder of the year with significant milestones anticipated in the near term and look forward to optimizing our opportunities to build value for all shareholders in the near and long-term.”

In addition, the company announced the presentation of updated results from the on-going study evaluating Berubicin, CNS Pharmaceuticals’ novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier, in a poster presentation at the 2023 SNO/ASCO CNS Cancer Conference, held Aug. 10-12, 2023, in San Francisco, California. The presentation is now available on the company’s website. “Berubicin has demonstrated its capability to be an innovative treatment in GBM that is safe and well tolerated, which has the potential to be a novel and effective therapy for this disease. Based on the results we’ve seen preclinically and in the clinic thus far, including these updated results from our on-going potentially pivotal study, we remain optimistic that Berubicin may provide a much needed clinical benefit for GBM patients,” said Sandra Silberman, MD, PhD, chief medical officer of CNS Pharmaceuticals. “We look forward to upcoming interim results that will evaluate Berubicin compared to the current standard of care (Lomustine) for second line therapy in this disease.”

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

CNS Pharmaceuticals Inc. (CNSP) Stock Research Links

CNSP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pizza: The Unlikely Symbol of Universal Togetherness

Updated Category News Views 0

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 0

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 0

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 4

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 0

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 0

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading
PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 0

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 5

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 0

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 7

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating Cybersecurity Excellence with CEH Hall of Fame 2025

Updated Category News Views 360

EC-Council Unveils Significant Findings on Ethical Hacking In a notable development for the cybersecurity field, EC-Council has recently presented the CEH Hall of Fame 2025 Industry Report, a comprehensive analysis that reveals how the Certified Ethical Hacker (CEH) certification is reshaping careers and enhancing national security. This data-focused report showcases the...

Continue Reading
CNN Implements $3.99 Monthly Paywall for Exclusive Content

Updated Category News Views 117

CNN Introduces Monthly Subscription for Premium Access CNN has recently announced a new paywall model for some users, requiring a monthly subscription of $3.99 for access to its online content. This pivotal decision marks CNN's strategic movement toward generating reliable digital revenue. A Shift Towards Subscription Models This initiative comes at a time when various...

Continue Reading
Maximizing Retirement Income: Smart Strategies for Couples

Updated Category News Views 306

Managing Income in Retirement: An Overview As retirees, many face the challenge of living on a limited nest egg, especially if their savings are modest. To navigate this, mastering the art of financial management in retirement becomes incredibly important. While Social Security provides a vital safety net for many, thorough planning and smart financial strategies can help...

Continue Reading
Growing Market for Paint Protection Film Expected to Thrive

Updated Category News Views 232

Introduction to the Paint Protection Film Market Austin—The paint protection film (PPF) market is witnessing remarkable growth, with projections indicating a valuation of USD 894.80 million within the next decade. This robust expansion, expected to develop at a compound annual growth rate (CAGR) of 6.01%, highlights the increasing priority consumers place on vehicle...

Continue Reading
Ericsson's Annual Report Highlights for Future Growth in Tech

Updated Category News Views 152

Ericsson's Annual Report Insights Ericsson, a leader in technology and communication innovations, has officially submitted its Annual Report on Form 20-F to the U.S. Securities and Exchange Commission (SEC). This report covers the company's operational performance and future strategies, reflecting its dedication to advancing mobile communication and connectivity...

Continue Reading